(Q38635027)

5 September 2017

title

CAR T-cells merge into the fast lane of cancer care (English)

1 reference

5 September 2017

2

David L Porter

1 reference

5 September 2017

1

Noelle V Frey

1 reference

5 September 2017

publication date

17 November 2015

1 reference

American Journal of Hematology

5 September 2017

published in

1 reference

5 September 2017

volume

91

1 reference

5 September 2017

issue

1

1 reference

5 September 2017

page(s)

146-150

1 reference

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

5 September 2017

cites work

1 reference

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

21 January 2018

1 reference

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Engineering lymphocyte subsets: tools, trials and tribulations

21 January 2018

1 reference

The promise and potential pitfalls of chimeric antigen receptors

21 January 2018

1 reference

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

21 January 2018

1 reference

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

21 January 2018

1 reference

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

21 January 2018

1 reference

The ABCs of artificial antigen presentation

21 January 2018

1 reference

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

21 January 2018

1 reference

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

21 January 2018

1 reference

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

21 January 2018

1 reference

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.

21 January 2018

1 reference

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)

21 January 2018

1 reference

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

21 January 2018

1 reference

Relapsed childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

21 January 2018

1 reference

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

21 January 2018

1 reference

Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL.

21 January 2018

1 reference

Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications

21 January 2018

1 reference

Toxicity management for patients receiving novel T-cell engaging therapies.

21 January 2018

1 reference

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.24238

1 reference

5 September 2017

1 reference